Business Context and Reporting Period
Rosecliff Acquisition Corp I, a blank-check company, filed this Form 8-K on April 17, 2023, reporting events occurring on April 11, 2023. The filing announces a definitive Business Combination Agreement with Spectral MD Holdings, Ltd. (“Spectral MD”).
Transaction Overview
At closing, two wholly owned subsidiaries of Rosecliff will merge with Spectral MD in a two-step merger. Spectral MD will become a wholly owned subsidiary initially, and the surviving entity will subsequently be a wholly owned subsidiary of the combined company. Rosecliff will be renamed to a name substantially similar to Spectral MD, Inc.
Outstanding Spectral MD shares will generally be converted into shares of the combined company. Spectral MD options and restricted stock units will generally be converted into corresponding awards of the combined company. The filing does not provide a clear transaction equity value, exchange ratio, projected ownership percentage, financing amount, or valuation.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit, cash flow, margin, debt, cash balance, or other operating financial metrics.
- The filing states that Spectral MD must provide certain unaudited consolidated financial statements in connection with the transaction process, but those statements are not included in this Form 8-K.
- The Sponsor Letter Agreement addresses potential accrued and unpaid parent expenses exceeding $3.25 million and provides for sponsor credits, forfeiture of sponsor shares, or potential Sponsor PIPE investments. The filing does not state whether the threshold will be exceeded or the final amount of any financing.
Material Changes and Transaction Terms
- The boards of both Rosecliff and Spectral MD unanimously approved the Business Combination Agreement, subject to required stockholder and regulatory approvals.
- Rosecliff’s sponsor agreed to vote in favor of the transaction, not redeem or transfer specified securities, and surrender its private placement warrants.
- Depending on Parent Closing Cash, the sponsor may retain between 750,000 and 1,500,000 sponsor shares, excluding shares associated with any Sponsor PIPE.
- Key Spectral MD stockholders agreed to support the transaction and vote against proposals that could prevent or breach the transaction agreements.
- At closing, the parties contemplate an amended registration rights and lock-up agreement. Transfer restrictions on specified securities generally end 180 days after closing.
Conditions, Outlook, and Risks
Closing is subject to customary conditions, including approval by Rosecliff and Spectral MD stockholders, effectiveness of an SEC Form S-4 registration statement and proxy statement, expiration or termination of the Hart-Scott-Rodino waiting period, absence of prohibitive legal orders, Nasdaq listing approval, and satisfaction of representations, warranties, covenants, and material-adverse-effect conditions.
The agreement may be terminated in specified circumstances, including mutual consent, uncured breaches, failure to close by September 30, 2023, governmental prohibition, failure to obtain required Rosecliff approvals, or a change in the Rosecliff board’s recommendation.
Key risks identified include failure to complete the transaction, inability to meet the business combination deadline or obtain an extension, failure to secure stockholder or regulatory approvals, Nasdaq listing issues, limited valuation support, potential litigation, financing requirements, market volatility, changing economic and regulatory conditions, disruption to Spectral MD’s operations, and failure to realize anticipated transaction benefits.
The filing states that it is not an offer to sell or solicitation to buy securities. Investors are directed to review the future Form S-4, definitive proxy statement/prospectus, and other SEC filings before making investment or voting decisions.
Important Facts to Verify
- Whether the Form S-4 registration statement becomes effective and the required stockholder approvals are obtained.
- The final exchange ratio, post-closing ownership structure, transaction valuation, and dilution from converted awards and sponsor securities.
- The amount of cash available at closing, including redemptions, PIPE financing, sponsor contributions, and transaction expenses.
- Whether the transaction closes by September 30, 2023, or whether the termination date is amended or extended.
- Whether the combined company receives and maintains Nasdaq listing approval.
- The unaudited and audited financial statements, financial projections, revenue outlook, cash needs, and risk factors to be included in subsequent filings.